Partnering

Partnering is a key to our ambition for 2030 and beyond

Our partnership strategy aims at a single objective: speed up the development of transformative treatments to significantly improve patient lives. We take a people-oriented approach to our partnerships, focusing on mutual value creation by combining our collective expertise.

Our Partnering Interests

Servier is in a phase of programmatic deal-making, especially in oncology and neurology. We aim to drive innovation by working closely with our partners to make a meaningful impact on patient lives.

In oncology, we primarily focus on opportunities from advanced research to late-stage clinical trials in:

Leukemia – AML, ALL, MDS, MPNs
Brain
GI – PDAC, CRC, BTC, Gastric, Esophageal and others
Modalities – Antibodies (mAb, ADC, bi-tri specific. TCE), small molecules

In neurology, we are primarily interested in rare neurological disorders and assets ranging from advanced research to late-stage clinical trials, such as:

Rare movement disorders – FA, SCA, MSA, PSP, HD
Neuromuscular disorders – ALS, SMA, DMD, FSHD, DM, MG
Refractory epilepsies – DS, LGS, JS, WS, other DEEs
Modalities –oligonucleotides, small molecules, antibodies

We are also actively seeking to form technological partnerships with the aim of accelerating the development of our therapeutic projects, particularly for the exploitation of data and artificial intelligence (see our partnership brochure below for more details).

Assets for Out-Licensing

If interested in any of the below assets, please reach out here. We’d welcome a discussion with interested parties.

Asset	Target	Modality	Phase	Treatment Area	Territory
S217879	NRF2 Activator	Small molecule	PCC	Metabolic Disease (NASH/MASH)	World
RHU030	Galectin-3	Monoclonal antibody	PCC	Immuno-inflammatory Oncology	World
S95041	CD40	Monoclonal antibody	PCC	Immuno-inflammatory	World
S95042	OX40	Monoclonal antibody	PCC	Immuno-inflammatory	World
SYM004	EGFR	Monoclonal antibody	Phase 2	Oncology	World
SYM015	MET	Monoclonal antibody	Phase 2a	Oncology	World

Why Partner with Servier?

At Servier, we have the resources and reach of a globally established pharmaceutical company combined with a long-term vision focused on developing transformative medicines for patients. Our unique value proposition enables us to build successful partnerships.

Patient-Oriented: Our first consideration is always what’s best for the patients we serve and how we can make the world a better place for them. Through our Patient Expert Council, we gain knowledge about the patient experience and guidance on many of our projects. We also partner with patient advocacy groups to support their initiatives and programs.
Fortified by Our Heritage: We are governed by a non-profit foundation and globally have commercial operations in more than 90 countries worldwide and alliance management expertise with more than 40 partnerships.
Invested in the Long-Term: We are not motivated by investors and have real decision-making flexibility, followed by the resources and network that can lead to agile environments and investments in multiple projects leading to quick results.
Fueling Discovery: Our strategy is to increase our investment into our R&D partnerships and away from life-cycle management. We are looking to invest in significant advances for the patients we serve, and offer scientific input, technological help and financial support for co-developing projects.

Download Our Brochure